Andreas Glenthøj
Copenhagen University Hospital, Rigshospitalet
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Glenthøj as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05935202 · Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesEuroBloodNet Association · not yet recruiting · Hereditary Red Blood Cell Disorder (Disorder) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:11 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).J Hematol Oncol · 2021271 citationsRCR 12.8
- Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.Psychiatry Res · 2007105 citationsRCR 3.1
- COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.Blood · 202282 citationsRCR 4.5
- Mitapivat versus Placebo for Pyruvate Kinase Deficiency.N Engl J Med · 202282 citationsRCR 6.2
- Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial.Eur J Heart Fail · 202365 citationsRCR 6.8
- Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.Lancet Haematol · 202247 citationsRCR 3.7
- 20 citationsRCR 6.2
- 10 citationsRCR 1.1
- Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.Blood Adv · 202410 citationsRCR 1.5
- Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.Am J Hematol · 20244 citationsRCR 0.5